NewsDialy
AbbVie is closing in on an acquisition of Apogee Therapeutics valued at nearly $11 billion, a move that would rank among the drug giant's largest purchases in recent years.
The deal arrives as Big Pharma companies accelerate efforts to replenish drug pipelines through dealmaking, with biotech M&A activity picking up pace across the sector.
What the Deal Means for AbbVie An acquisition of this scale represents a significant pipeline bet for AbbVie.
Biotech buyouts of this size are typically driven by the acquirer's need to secure future revenue streams — particularly when blockbuster drugs face patent expirations that erode sales.
Keep reading